The Protective Effect of Platelet-rich Plasma Administrated on Ovarian Function in Female Rats with Cy-induced Ovarian Damage

Overview

Journal J Assist Reprod Genet

Publisher Springer

Specialties Genetics
Reproductive Medicine

Date 2020 Feb 6

PMID 32020412

Citations 13

Authors

Pinar Ozcan

Taha Takmaz

Olgu Enis Tok

Sevde Islek

Esra Nur Yigit

Cem Ficicioglu

Affiliations

Soon will be listed here.

Abstract

Purpose: We evaluated the protective effect of PRP on ovarian function in female rats with cyclophosphamide (Cy)-induced ovarian damage.

Methods: Thirty-two adult female Sprague-Dawley rats were randomly divided into four groups. Group 1 (control-sodium chloride 0.9%; 1 mL/kg, single-dose ip injection), group 2 (Cy); 75 mg/kg, single-dose ip injection and sodium chloride 0.9% (1 mL/kg, single-dose ip injection), group 3 Cy plus PRP, Cy (75 mg/kg, single-dose and PRP (200 μl, single-dose) ip injection), group 4 (PRP, 200 μl, single-dose ip injection). Primordial, antral, and atretic follicle counts; serum anti-Müllerian hormone (AMH) levels; AMH-positive granulosa cells; and gene expression analysis of Ddx4 were assessed.

Results: Serum AMH levels were significantly lower in group 2 compared to groups 1, 3, and 4 (p < 0.01, p < 0.01, and p = 0.04, respectively). A significant difference was found in the primordial, primary, secondary, antral, and atretic follicle counts between all groups (p < 0.01). There was a statistically significant difference in AMH-positive staining primary, secondary, and antral follicles count between the groups (p < 0.01). There was a statistically significant difference in primary, secondary, and antral AMH positive staining follicle intensity score between the groups (p < 0.01). Ddx4 expression in group 4 was highest compared to other groups.

Conclusion: Our study may provide evidence that PRP could protect ovarian function against ovarian damage induced by Cy. It could lead to improved primordial, primary, secondary, and antral follicle numbers.

Citing Articles

Novel Molecular Mechanisms Underlying the Ameliorative Effect of Platelet-Rich Plasma against Electron Radiation-Induced Premature Ovarian Failure.

Demyashkin G, Vadyukhin M, Murtazalieva Z, Pugacheva E, Schekin V, Bimurzaeva M Int J Mol Sci. 2024; 25(18).

PMID: 39337598 PMC: 11432445. DOI: 10.3390/ijms251810115.

Intraovarian platelet-rich plasma injection in poor responders.

Devenutto L, Valzacchi G, Ercolano M, Etchegoyen O JBRA Assist Reprod. 2024; 28(3):450-456.

PMID: 38838163 PMC: 11349265. DOI: 10.5935/1518-0557.20240031.

Platelet-rich plasma (PRP) treatment of the ovaries significantly improves fertility parameters and reproductive outcomes in diminished ovarian reserve patients: a systematic review and meta-analysis.

Elias M, Konya M, Kekk Z, Turan C, das Virgens I, Toth R J Ovarian Res. 2024; 17(1):104.

PMID: 38760869 PMC: 11100055. DOI: 10.1186/s13048-024-01423-2.

Therapeutic roles of platelet-rich plasma to restore female reproductive and endocrine dysfunction.

Wang X, Li J, Lu W, Gao F, Zhang S, Li J Front Endocrinol (Lausanne). 2024; 15:1374382.

PMID: 38654928 PMC: 11035829. DOI: 10.3389/fendo.2024.1374382.

Protective Effect of Glutathione Administration on Ovarian Function in Female Rats with Cyclophosphamide-Induced Ovarian Damage.

Yurttancikmaz E, Ozcan P, Tanoglu F, Tok O, Timur H, Cetin C Gynecol Obstet Invest. 2024; 89(2):120-130.

PMID: 38253037 PMC: 11126202. DOI: 10.1159/000536055.

References

Bukovsky A . Novel methods of treating ovarian infertility in older and POF women, testicular infertility, and other human functional diseases. Reprod Biol Endocrinol. 2015; 13:10. PMC: 4414002. DOI: 10.1186/s12958-015-0001-8. View

Pintat J, Silvestre A, Magalon G, Gadeau A, Pesquer L, Perozziello A . Intra-articular Injection of Mesenchymal Stem Cells and Platelet-Rich Plasma to Treat Patellofemoral Osteoarthritis: Preliminary Results of a Long-Term Pilot Study. J Vasc Interv Radiol. 2017; 28(12):1708-1713. DOI: 10.1016/j.jvir.2017.08.004. View

Fabi S, Sundaram H . The potential of topical and injectable growth factors and cytokines for skin rejuvenation. Facial Plast Surg. 2014; 30(2):157-71. DOI: 10.1055/s-0034-1372423. View

Yeh J, Kim B, Peresie J . Protection against cisplatin-induced ovarian damage by the antioxidant sodium 2-mercaptoethanesulfonate (mesna) in female rats. Am J Obstet Gynecol. 2008; 198(4):463.e1-6. DOI: 10.1016/j.ajog.2007.12.027. View

Lee K, Wilson J, Rabago D, Baer G, Jacobson J, Borrero C . Musculoskeletal applications of platelet-rich plasma: fad or future?. AJR Am J Roentgenol. 2011; 196(3):628-36. DOI: 10.2214/AJR.10.5975. View

Marx R, Carlson E, Eichstaedt R, Schimmele S, Strauss J, Georgeff K . Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998; 85(6):638-46. DOI: 10.1016/s1079-2104(98)90029-4. View

Anderson R, Fulton N, Cowan G, Coutts S, Saunders P . Conserved and divergent patterns of expression of DAZL, VASA and OCT4 in the germ cells of the human fetal ovary and testis. BMC Dev Biol. 2007; 7:136. PMC: 2211489. DOI: 10.1186/1471-213X-7-136. View

Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S . Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility. Sci Transl Med. 2013; 5(185):185ra62. DOI: 10.1126/scitranslmed.3005402. View

Roness H, Kashi O, Meirow D . Prevention of chemotherapy-induced ovarian damage. Fertil Steril. 2015; 105(1):20-9. DOI: 10.1016/j.fertnstert.2015.11.043. View

10.

Ben-Aharon I, Meizner I, Granot T, Uri S, Hasky N, Rizel S . Chemotherapy-induced ovarian failure as a prototype for acute vascular toxicity. Oncologist. 2012; 17(11):1386-93. PMC: 3500358. DOI: 10.1634/theoncologist.2012-0172. View

11.

Van Kasteren Y . Treatment concepts for premature ovarian failure. J Soc Gynecol Investig. 2001; 8(1 Suppl Proceedings):S58-9. View

12.

Huang Q, Liu B, Jiang R, Liao S, Wei Z, Bi Y . G-CSF-mobilized peripheral blood mononuclear cells combined with platelet-rich plasma accelerate restoration of ovarian function in cyclophosphamide-induced POI rats†. Biol Reprod. 2019; 101(1):91-101. DOI: 10.1093/biolre/ioz077. View

13.

Dehghani F, Sotoude N, Bordbar H, Panjeshahin M, Karbalay-Doust S . The use of platelet-rich plasma (PRP) to improve structural impairment of rat testis induced by busulfan. Platelets. 2018; 30(4):513-520. DOI: 10.1080/09537104.2018.1478400. View

14.

Bir S, Esaki J, Marui A, Yamahara K, Tsubota H, Ikeda T . Angiogenic properties of sustained release platelet-rich plasma: characterization in-vitro and in the ischemic hind limb of the mouse. J Vasc Surg. 2009; 50(4):870-879.e2. DOI: 10.1016/j.jvs.2009.06.016. View

15.

Blumenfeld Z . Chemotherapy and fertility. Best Pract Res Clin Obstet Gynaecol. 2012; 26(3):379-90. DOI: 10.1016/j.bpobgyn.2011.11.008. View

16.

Guo K, Li C, Wang X, He D, Zheng P . Germ stem cells are active in postnatal mouse ovary under physiological conditions. Mol Hum Reprod. 2016; 22(5):316-28. PMC: 4847614. DOI: 10.1093/molehr/gaw015. View

17.

Morgan S, Anderson R, Gourley C, Wallace W, Spears N . How do chemotherapeutic agents damage the ovary?. Hum Reprod Update. 2012; 18(5):525-35. DOI: 10.1093/humupd/dms022. View

18.

Li W, Enomoto M, Ukegawa M, Hirai T, Sotome S, Wakabayashi Y . Subcutaneous injections of platelet-rich plasma into skin flaps modulate proangiogenic gene expression and improve survival rates. Plast Reconstr Surg. 2012; 129(4):858-866. DOI: 10.1097/PRS.0b013e3182450ac9. View

19.

Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K . Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging (Albany NY). 2011; 3(8):782-93. PMC: 3184979. DOI: 10.18632/aging.100363. View

20.

Woad K, Watkins W, Prendergast D, Shelling A . The genetic basis of premature ovarian failure. Aust N Z J Obstet Gynaecol. 2006; 46(3):242-4. DOI: 10.1111/j.1479-828X.2006.00585.x. View